The dawn of RAS-targeted therapy: a landmark breakthrough of daraxonrasib in pancreatic cancer

Chenchen Liu; Liang Liu

doi:10.1007/s44272-026-00072-4

Clinical Cancer Bulletin ›› 2026, Vol. 5 ›› Issue (1) :20 DOI: 10.1007/s44272-026-00072-4

Commentary

article-commentary

The dawn of RAS-targeted therapy: a landmark breakthrough of daraxonrasib in pancreatic cancer

Chenchen Liu ¹^,²^,³
, Liang Liu ¹^,²^,³^,^a

Author information +

History +

PDF

Cite this article

Download citation ▾

Chenchen Liu, Liang Liu. The dawn of RAS-targeted therapy: a landmark breakthrough of daraxonrasib in pancreatic cancer. Clinical Cancer Bulletin, 2026, 5 (1) : 20 DOI:10.1007/s44272-026-00072-4

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Park W, Chawla A, O’Reilly EM. Pancreatic cancer: a review. JAMA, 2021, 326(9): 851-862.

[2]	Siegel RL, Kratzer TB, Wagle NS, et al.Cancer statistics, 2026. CA Cancer J Clin, 2026, 76: e70043.

[3]	Conroy T, Desseigne F, Ychou M, et al.FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med, 2011, 364(19): 1817-1825.

[4]	Von Hoff DD, Ervin T, Arena FP, et al.Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med, 2013, 369(18): 1691-1703.

[5]	Dayyani F, Macarulla T, Johnson A, et al.Second-line treatment options for patients with metastatic pancreatic ductal adenocarcinoma: a systematic literature review. Cancer Treat Rev, 2023, 113: 102502.

[6]	Wolpin BM, Park W, Garrido-Laguna I, et al.Daraxonrasib in previously treated advanced RAS-mutated pancreatic cancer. N Engl J Med, 2026, 394(18): 1790-1802.

[7]	O’Reilly EM, Wainberg ZA, Hendifar AE, et al.Daraxonrasib or chemotherapy in previously treated metastatic pancreatic cancer. N Engl J Med, 2026, 395(4): 325-337.

[8]	Bailey P, Chang DK, Nones K, et al.Genomic analyses identify molecular subtypes of pancreatic cancer. Nature, 2016, 531(7592): 47-52.

[9]	Ardalan B, Ciner A, Baca Y, et al.Distinct molecular and clinical features of specific variants of KRAS codon 12 in pancreatic adenocarcinoma. Clin Cancer Res, 2025, 31(6): 1082-1090.

[10]	Strickler JH, Satake H, George TJ, et al.Sotorasib in KRAS p.G12C-mutated advanced pancreatic cancer. N Engl J Med, 2023, 388(1): 33-43.

[11]	Holderfield M, Lee BJ, Jiang JJ, et al.Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy. Nature, 2024, 629(8013): 919-926.

[12]	Jiang JJ, Jiang LY, Maldonato BJ, et al.Translational and therapeutic evaluation of RAS-GTP inhibition by RMC-6236 in RAS-driven cancers. Cancer Discov, 2024, 14(6): 994-1017.